Perspectives on African pharma markets, commercial strategy, and the forces shaping how life sciences companies operate across the continent.
At Helix Bridge, we believe that sharing rigorous, grounded thinking makes the field better for everyone — including our clients, our peers, and ultimately the patients who depend on a well-functioning African pharma ecosystem. These articles are written by practitioners, for practitioners.
We do not write to fill a content calendar. We write when we have something specific, useful, and honest to say about the markets and challenges our clients navigate.
Pharma companies entering African markets frequently rely on commercial models borrowed from other emerging markets — Latin America, South-East Asia, Eastern Europe — and are surprised when they underperform. Sub-Saharan and North African markets require purpose-built GTM architectures that account for channel fragmentation, regulatory heterogeneity, and informal distribution dynamics that simply do not exist elsewhere.
Commercial excellence in African pharma markets is not about installing a CRM or redesigning territories in isolation — it is about connecting salesforce effectiveness, marketing precision, and pricing discipline into an integrated commercial system that delivers measurable P&L improvement. Here is what that connection looks like in practice, and where most organisations break the chain.
Every year, pharma companies sign distribution agreements in African markets on the strength of desk research, broker recommendations, or regional reputation alone — and most of them pay for it. Genuine market intelligence in Africa requires field visits, health authority conversations, and distributor reference checks that cannot be replicated from a laptop. The companies that expand successfully are the ones that understand this before they commit.
Africa's pharma markets are defined by volatility, uncertainty, complexity, and ambiguity — the VUCA acronym that consultants use and operators live. But the companies that thrive in these conditions are not the ones that avoid the complexity; they are the ones that build commercial models specifically designed to operate within it. Here is what that looks like, and why the VUCA environment is as much an opportunity as it is a risk.
